144 - Auto-Injectors, Pen Injectors, Challenges in Product Development, Sponsors and CDMO's with David DeSalvo
David DeSalvo, Vice-President of Combination Product Development at Kindeva Drug Delivery, details his career trajectory from BD to SHL, Emergent BioSolutions, and finally Kindeva. He distinguishes between pen injectors, auto-injectors, and wearable devices, emphasizing that while connectivity is inevitable, it often adds unnecessary complexity and use errors if not carefully managed. DeSalvo discusses the challenges of transitioning between sponsor and CDMO perspectives, noting that successful partnerships require transparency rather than assuming the other side has the better view. He highlights the importance of balancing innovation with commercial viability, citing early experiences at BD where advanced technologies failed to reach the market due to cost and lack of payer demand.